SOURCE: Helix BioPharma Corp.

Helix BioPharma Corp.

June 27, 2016 07:30 ET

Helix BioPharma Corp. Announces L-DOS47 Immuno-Oncology Scientific Presentation at the Medical University of Warsaw

AURORA, ON--(Marketwired - Jun 27, 2016) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) ("Helix" or the "Company"), a immune-oncology company developing drug candidates for the prevention and treatment of cancer, today announced that Helix's Chief Scientific Officer, Dr. Heman Chao will be making a presentation on Tuesday, June 28, 2016 at the Strategies Towards Excellence in Immuno-Oncology symposium at the Medical University of Warsaw in Poland.

Dr. Chao's presentation entitled, Therapeutic Strategy Against Tumour Acidity Induced Immune-Suppression, will discuss the potential benefits of Helix's DOS47 platform in the treatment of cancer. The slide portion of the presentation will be made available on Helix's website for viewing at

About L-DOS47

L-DOS47 is Helix's first immunoconjugate based drug candidate in development based on the Company's novel DOS47 platform technology, which is designed to use an innovative approach to modify the microenvironmental conditions of cancer cells in a manner that leads to their destruction.

About Helix BioPharma Corp.

Helix BioPharma Corp. is an immuno-oncology company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the potential benefits of Helix's DOS47 platform in the treatment of cancer. Forward-looking statements, which may be identified by words including, without limitation, "will", "potential", "benefits" and other similar expressions, are intended to provide information about management's current plans and expectations regarding future operations.

Although Helix believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties that may cause actual results or events to differ materially from those anticipated and no assurance can be given that these expectations will be realized, and undue reliance should not be placed on such statements. Risk factors that could cause actual results or events to differ materially from the forward-looking statements include, without limitation, (i) the inherent uncertainty involved in scientific research and drug development; (ii) the risks associated with delay or inability to complete clinical trials successfully; (iii) need to secure additional financing on terms satisfactory to Helix or at all; (iv) clinical trials that yield negative results, or results that do not justify future clinical development, including that the Polish Phase I/II clinical trial for L-DOS47 will yield negative results; and (v) those risks and uncertainties affecting the company as more fully described in Helix's most recent Annual Information Form, including under the headings "Forward-Looking Statements" and "Risk Factors", filed with the Canadian Securities Administrators at (together, the "Helix Risk Factors"). Certain material factors or assumptions are applied in making the forward-looking statements, including, without limitation, that the Helix Risk Factors will not cause Helix's actual results or events to differ materially from the forward-looking statements. 

Forward-looking statements and information are based on the beliefs, assumptions and expectations of Helix's management on the date of this news release, and Helix does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions or expectations, or other circumstances change, except as required by law.

Contact Information

  • Investor Relations
    Helix BioPharma Corp.
    3-305 Industrial Parkway South
    Aurora, Ontario, L4G 6X7
    Tel: 905 841-2300